2nd European Oncology and Immuno-Oncology
Drug Discovery Symposium, Basel

How to Overcome Preclinical Development Hurdles
and Accelerate Transition through Clinical Trials

Date: Tuesday 22nd October, 2019 9:00-17:00
Venue: Hotel Stücki, Badenstrasse 1, 4057 Basel

Oncology and Immuno-Oncology Drug Discovery Symposium, Basel

Registration Now Open

Learn from experts about their current therapeutic approach to today’s oncology challenges. Gain insight on how to further support your oncology and immuno-oncology drug development programs, from preclinical and translational studies, to research in the clinic, by attending the Champions Oncology drug discovery symposium.

RESERVE YOUR SEAT NOW – FREE REGISTRATION

Who Should Attend

R&D, discovery, preclinical and translational teams from pharma, biotech, and academia


Presentations and Speakers



Keynote Speaker: Dr. Bruno Gomes

HEAD OF BIOMARKERS ONCOLOGY, ROCHE

Title: Challenges and opportunities for biomarkers in early clinical development


Dr. Andreas Katopodis

CEO, ANAVEON AG

Title: Re-Focusing IL-2 to fuel anti-cancer immunity


Dr. Raj Lehal

CSO, CELLESTIA BIOTECH AG

Title: Discovery and development of a first-in-class protein-protein interaction inhibitor targeting the NOTCH pathway


Dr. Marina Udier

CEO, NOUSCOM

Title: Changing the game with best-in-class neoantigen cancer vaccine


Dr. Henning Lauterbach

EXECUTIVE DIRECTOR – PRECLINICAL R&D, HOOKIPA PHARMA INC.

Title: Live attenuated arenavirus-based vectors for active cancer immunotherapy


Dr. Jayesh Majithiya, MPharm, PhD

SENIOR SCIENTIST TRANSLATIONAL BIOLOGY, CRESCENDO BIOLOGICS LTD

Title: CB307, A novel T-cell agonist humabody therapeutic for PSMA-positive tumours

Dr. Jayesh Majithiya, MPharm, PhD

Dr. Zaki Sellam

COO, ATICURE

Title: T cell therapies – From challenges to promising perspectives Insights to ATICure new generation of T cell therapies


Dr. Patrick Nef

CEO, TRANSCURE BIOSERVICES

Title: Transient human cytokine expression for advanced and physiological full human immune system reconstitution in hu-NCG for CDX and PDX’s preclinical in vivo pharmacology studies


Dr. Amy Wesa

DIRECTOR OF IMMUNO-ONCOLOGY RESEARCH, CHAMPIONS ONCOLOGY, INC.

Title: Emerging preclinical models in oncology: ex vivo platforms and humanized mouse models

Amy Wesa